Literature DB >> 27976824

Overexpression of cannabinoid receptor 1 in esophageal squamous cell carcinoma is correlated with metastasis to lymph nodes and distant organs, and poor prognosis.

Naoki Hijiya1, Tomotaka Shibata2, Tsutomu Daa3, Ryoji Hamanaka4, Tomohisa Uchida1, Keiko Matsuura5, Yoshiyuki Tsukamoto1, Chisato Nakada1, Hidekatsu Iha6, Masafumi Inomata2, Masatsugu Moriyama1.   

Abstract

In patients with esophageal squamous cell carcinoma (ESCC), the status of metastasis to lymph nodes is strongly associated with prognosis. Consequently, development of a biomarker to detect the presence of metastasis would be clinically valuable. In this study, we found that overexpression of cannabinoid receptor 1 (CB1R) was applicable as a marker for prediction of metastasis in ESCC. CB1R overexpression was detected immunohistochemically in 54 of 88 cases (61.4%). The intensity of CB1R expression was uniform in both intraepithelial and invasive regions in each case, and was significantly correlated with the status of metastasis to lymph nodes (P = 0.046) and distant organs (P = 0.047). Furthermore, multivariate analysis revealed that CB1R overexpression was independently associated with poor prognosis (P = 0.019). Biological analysis of CB1R overexpression using ESCC cell lines revealed that CB1R activation appeared to promote cell proliferation and invasion. On the basis of these findings, we propose that evaluation of CB1R expression status in biopsy specimens of ESCC using immunohistochemistry might be clinically useful for prediction of metastasis to lymph nodes and distant organs.
© 2016 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cannabinoid receptor 1; esophageal squamous cell carcinoma; immunohistochemistry; lymph node metastasis; predictive marker

Mesh:

Substances:

Year:  2016        PMID: 27976824     DOI: 10.1111/pin.12495

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

Authors:  Chao Liu; Sayed H Sadat; Koji Ebisumoto; Akihiro Sakai; Bharat A Panuganti; Shuling Ren; Yusuke Goto; Sunny Haft; Takahito Fukusumi; Mizuo Ando; Yuki Saito; Theresa Guo; Pablo Tamayo; Huwate Yeerna; William Kim; Jacqueline Hubbard; Andrew B Sharabi; J Silvio Gutkind; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

2.  Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer.

Authors:  Cong-Kai Luo; Pei-Hsuan Chou; Shang-Kok Ng; Wen-Yen Lin; Tzu-Tang Wei
Journal:  Cancer Gene Ther       Date:  2021-05-18       Impact factor: 5.987

3.  LncRNA XIST accelerates burn wound healing by promoting M2 macrophage polarization through targeting IL-33 via miR-19b.

Authors:  Li Pi; Bairong Fang; Xianxi Meng; Li Qian
Journal:  Cell Death Discov       Date:  2022-04-21

4.  ∆9-tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer.

Authors:  Yingzhi Zhang; Wei Zheng; Kewei Shen; Weiwei Shen
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

Review 5.  Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far.

Authors:  Jonathan Gotfried; Rahul Kataria; Ron Schey
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01

Review 6.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Authors:  Vicente Martínez; Amaia Iriondo De-Hond; Francesca Borrelli; Raffaele Capasso; María Dolores Del Castillo; Raquel Abalo
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 7.  Impact of Cannabinoid Compounds on Skin Cancer.

Authors:  Robert Ramer; Franziska Wendt; Felix Wittig; Mirijam Schäfer; Lars Boeckmann; Steffen Emmert; Burkhard Hinz
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.